Neurology Advisor Contributing Writer

A combination of dalfampridine extended-release and physical therapy (PT) has shown efficacy for improving gait in people with multiple sclerosis

The MS and monophasic ADS groups were compared using quantified melanin measurements via the DSM II Colorimeter; self-reported skin tones of fair, medium, olive, or dark; a self-reported race; and skin tone, which was self-reported using 10 numerical panels of color.

The protocol authors propose a more objective method of managing medication adherence through a profile performed by an occupational therapist.

This study analyzed results from SUNBEAM (ClinicalTrials.gov Identifier: NCT02294058) and RADIANCE (ClinicalTrials.gov Identifier: NCT01628393), 2 double-blind, randomized, phase 3 trials.

Due to the increased risk for urinary tract infections (UTIs) in people with MS and similar CNS demyelinating diseases, as well as the tendency of UTIs to trigger more MS flares, the affected population are subject to a large number of unneeded antibiotic prescriptions and asymptomatic bacteriuria treatments.

Brain volume loss was smaller for all groups after treatment with fingolimod.

TG1101-RMS201 was a multicenter, placebo-controlled, phase 2, 52-week study designed to evaluate the optimal infusion and safety of ublituximab for relapsing multiple sclerosis.

Analysis of yearly lymphocyte counts showed a declining occurrence of all grades of lymphopenia over time, and by year 9, subjects exhibited no cases of lymphopenia.